Article Text

Download PDFPDF

P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
  1. S Jallad1,
  2. P Thomas1,
  3. M Newport2 and
  4. F Kern2
  1. Aff1 grid.416225.60000 0000 8610 7239Royal Sussex County HospitalUrology Brighton UK
  2. Aff2 grid.414601.60000 0000 8853 076XBrighton and Sussex Medical SchoolUrology Brighton UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Intravesical BCG is an example of the importance of immunotherapy in cancer treatment. It has been used since the 1970s as it has a major impact in preventing or delaying bladder cancer recurrence and possibly progression. Unfortunately 20-30% of patients who receive this treatment do not respond and they are at high risk of dying from their disease. Being able to predict response to treatment would be an invaluable tool in those patients and would help in directing them to the appropriate treatment modalities. We investigated whether immunological markers in blood can predict outcome.


Patients with high risk non-invasive bladder cancer and due to have BCG immunotherapy were included. Blood samples were obtained before and after BCG-induction treatment. In vitro stimulation of peripheral-blood mononuclear cells with PPD which were then labelled with extra and intracellular markers in order to assess the differentiation and activation status of T-cells.


13 patients had no recurrence on follow-up cystoscopy while 6 had persistent disease. Differences were seen between the two groups in mean percentage of Interferon gamma positive (INFγ+) CD4 in response to PPD stimulation; 1.84% (±1.58) in the recurrence-free group versus 0.54% (±0.72) in the recurrence group [P value 0.0252]. This was more clear in the specialised subset [CCR7-CD27-CD28+]; 2.46% (±1.96) and 0.77% (±0.80) respectively [P value 0.0168]. And in the [CCR7-CD27-CD28+] subset; 5.07% (±4.19) and 1.12% (±1.25) respectively [P Value 0.0067]. The mean percentages of pre-treatment tumour necrosis factor positive (TNF+) cells were also significantly different in the [CCR7-CD27-CD28+] subset; 8.82% (±6.06) and 3.10% (±3.81) respectively [P value 0.0246].


In bladder cancer immunotherapy, the percentage of PPD inducible INFγ+ and TNF+ CD4 cells can potentially predict outcome to treatment.